
Top 3 Healthcare Stocks to Watch in 2027: Dr Lal PathLabs, Metropolis and Vijaya Diagnostic
Dr Lal PathLabs Rs 1,957.00, Q2 PAT +27.4%. Metropolis Rs 567.10, Q2 PAT +42.7%. Vijaya Diagnostic Rs 1,536.00, Q2 PAT +37.4%. Prices as of 18 Nov 2026.
Updated: 19 Nov 2026 • 1:03 pm
Posted by:

Quick Answer
The healthcare stocks to watch in 2027 are Dr Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostic Centre, based on their latest results, returns and balance sheets. Metropolis combines the fastest recent profit growth with the lowest valuation, while Dr Lal PathLabs earns the highest return on equity. The best figures in the group are 42.7% quarterly profit growth, a PE of 51.93 and a return on equity of 21.32%. Each stock has its own risks, so investors should match the choice to their holding period and risk appetite.
The healthcare stocks to watch in 2027 are best picked on reported numbers. Preventive health check-ups, specialised tests and the shift from small labs to organised chains are driving diagnostic companies, and all three leaders on this list grew profit by more than 27% in the September 2026 quarter.
This list covers Dr Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostic Centre. Each company is assessed on quarterly and annual profit growth, return on equity, debt, valuation and where its share price sits in its 52-week range. Prices are as of the 18 November 2026 close.
Click Here – Get Free Investment Predictions
Top 3 Healthcare Stocks to Watch in 2027 at a Glance
Dr Lal PathLabs, Metropolis and Vijaya Diagnostic have a combined market capitalisation of about Rs 60,501 crore. The table below compares these healthcare stocks to watch in 2027 on the metrics that matter most for long-term investors.
| Metric | Dr Lal PathLabs | Metropolis | Vijaya Diagnostic |
|---|---|---|---|
| Company | Dr Lal PathLabs | Metropolis Healthcare | Vijaya Diagnostic Centre |
| NSE Symbol | LALPATHLAB | METROPOLIS | VIJAYA |
| Share Price (Rs) | 1,957.00 | 567.10 | 1,536.00 |
| 52-Week Closing High (Rs) | 2,029.40 | 602.10 | 1,570.70 |
| 52-Week Closing Low (Rs) | 1,307.60 | 421.75 | 861.40 |
| Market Cap (Rs Cr) | 32,976 | 11,704 | 15,821 |
| PE Ratio | 56.08 | 51.93 | 77.66 |
| ROE | 21.32% | 13.66% | 19.26% |
| Debt to Equity | 0.09 | 0.16 | 0.48 |
| Dividend Yield | 1.04% | 0.89% | 0.13% |
On valuation, the stocks trade at the following PE ratios: Dr Lal PathLabs at 56.08 against an industry PE of 63.96; Metropolis at 51.93 against an industry PE of 63.96; Vijaya Diagnostic at 77.66 against an industry PE of 63.96. Dr Lal PathLabs and Metropolis trade below the industry multiple, while Vijaya Diagnostic carries a premium that the market usually pays for faster growth or stronger returns.
Why Are These the Healthcare Stocks to Watch in 2027?
These three made the list of healthcare stocks to watch in 2027 because of earnings delivery and balance sheet quality. Diagnostic chains are among the most profitable healthcare businesses in India because they need little debt, earn cash upfront and grow by adding collection centres. This list focuses on the three largest listed diagnostic companies.
In the September 2026 quarter, net profit grew 27.4% at Dr Lal PathLabs, 42.7% at Metropolis and 37.4% at Vijaya Diagnostic. Return on equity ranges from 13.66% to 21.32%, which shows how efficiently each company uses shareholder capital. Dr Lal PathLabs runs with little or no debt.
What Could Drive Healthcare Stocks in 2027?
Healthcare stocks in the diagnostics space will be driven in 2027 by test volumes per patient, the share of specialised and genomic tests, and expansion into smaller towns where organised labs are still scarce.
Pricing competition from online diagnostic platforms and hospital labs is the main pressure point, so investors should track revenue per patient alongside overall growth.
1. Dr Lal PathLabs: Diagnostic Leader with High ROE
Dr Lal PathLabs is one of India's largest diagnostic chains, with a strong base in north India and a network of labs and patient service centres across the country.
Dr Lal PathLabs Financial Performance
| Metric | Latest | Year Earlier | Change |
|---|---|---|---|
| Revenue (Rs Cr) | 908.20 | 755.40 | +20.2% |
| Net Profit (Rs Cr) | 193.90 | 152.20 | +27.4% |
| Revenue FY26 vs FY25 (Rs Cr) | 2,864.18 | 2,554.82 | +12.1% |
| Net Profit FY26 vs FY25 (Rs Cr) | 509.75 | 492.25 | +3.6% |
For FY26, revenue came in at Rs 2,864.18 crore (+12.1%), and net profit rose 3.6% to Rs 509.75 crore. Net profit has compounded at about 9.8% a year from FY22 to FY26.
What to Watch in Dr Lal PathLabs for 2027
Dr Lal PathLabs grew September 2026 quarter net profit 27.4% to Rs 193.90 crore on 20.2% higher revenue, and it has the highest ROE of the three at 21.32% with almost no debt. Investors should track growth in east and south India, where it is expanding. The stock closed at Rs 1,957.00 on 18 November 2026, about 3.6% below its 52-week closing high of Rs 2,029.40 and 49.7% above its 52-week closing low of Rs 1,307.60.
2. Metropolis Healthcare: Specialised Testing with Profit Recovery
Metropolis Healthcare runs a large diagnostic network with a strong presence in west and south India and a focus on specialised tests such as genetics and oncology.
Metropolis Financial Performance
| Metric | Latest | Year Earlier | Change |
|---|---|---|---|
| Revenue (Rs Cr) | 505.31 | 430.08 | +17.5% |
| Net Profit (Rs Cr) | 75.48 | 52.89 | +42.7% |
| Revenue FY26 vs FY25 (Rs Cr) | 1,671.43 | 1,346.32 | +24.1% |
| Net Profit FY26 vs FY25 (Rs Cr) | 191.18 | 145.51 | +31.4% |
What to Watch in Metropolis for 2027
Metropolis grew September 2026 quarter net profit 42.7% to Rs 75.48 crore, the fastest in this group, and FY26 profit rose 31.4%. Its PE of 51.93 is the lowest of the three. Investors should track whether recent acquisitions add to margins as they are integrated. The stock closed at Rs 567.10 on 18 November 2026, about 5.8% below its 52-week closing high of Rs 602.10 and 34.5% above its 52-week closing low of Rs 421.75.
Compare Healthcare Stocks on the Univest Screener
3. Vijaya Diagnostic Centre: Integrated Radiology and Pathology Chain
Vijaya Diagnostic Centre offers both pathology and radiology services, with a strong base in Telangana and Andhra Pradesh and expansion into Kolkata and other eastern markets.
Vijaya Diagnostic Financial Performance
| Metric | Latest | Year Earlier | Change |
|---|---|---|---|
| Revenue (Rs Cr) | 260.34 | 207.81 | +25.3% |
| Net Profit (Rs Cr) | 59.47 | 43.28 | +37.4% |
| Revenue FY26 vs FY25 (Rs Cr) | 835 | 699.71 | +19.3% |
| Net Profit FY26 vs FY25 (Rs Cr) | 172.98 | 143.79 | +20.3% |
For FY26, revenue came in at Rs 835 crore (+19.3%), and net profit rose 20.3% to Rs 172.98 crore. Net profit has compounded at about 11.8% a year from FY22 to FY26.
What to Watch in Vijaya Diagnostic for 2027
Vijaya Diagnostic grew September 2026 quarter revenue 25.3% and net profit 37.4%, and its net profit has grown in each of the last three years. The stock is close to its 52-week closing high and trades at a PE of 77.66, so investors should be careful about entry levels. The stock closed at Rs 1,536.00 on 18 November 2026.
How Do Dr Lal PathLabs, Metropolis and Vijaya Diagnostic Compare?
The table below puts quarterly growth, annual profit, valuation and price position for the three healthcare stocks side by side.
| Metric | Dr Lal PathLabs | Metropolis | Vijaya Diagnostic |
|---|---|---|---|
| Q2 Net Profit Growth | +27.4% | +42.7% | +37.4% |
| Latest Annual Net Profit (Rs Cr) | 509.75 | 191.18 | 172.98 |
| PE vs Industry PE | 56.08 vs 63.96 | 51.93 vs 63.96 | 77.66 vs 63.96 |
| Distance from 52-Week Closing High | 3.6% below | 5.8% below | 2.2% below |
For investors building a list of healthcare stocks to watch in 2027, the right pick depends on priorities. Those who want growth momentum and valuation comfort may track Metropolis and investors who want capital efficiency may prefer Dr Lal PathLabs. Vijaya Diagnostic gives exposure to a different part of the sector.
Key Risks for Healthcare Stocks in 2027
Even the strongest healthcare stocks to watch in 2027 carry risks that investors should weigh before buying.
Price competition: Online diagnostic platforms and hospital labs offer discounts that can pressure pricing.
Regional concentration: Each chain earns a large share of revenue from one region, so local competition matters.
Valuation: All three trade at PE ratios above 50, which leaves little room for slower growth.
Valuation: Vijaya Diagnostic trades above the industry PE, so a slowdown in growth can lead to price corrections. Staggered buying helps manage entry risk.
Download the Univest iOS App or Univest Android App to track Dr Lal PathLabs, Metropolis and Vijaya Diagnostic live and get daily stock research.
Conclusion
Dr Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostic Centre stand out among healthcare stocks to watch in 2027 on growth, returns and balance sheet strength. Before investing, compare each stock's PE with its profit growth, check where it trades in its 52-week range, and track the December and March quarter results to confirm the trend into 2027. Building positions gradually suits a sector where earnings can swing with price competition.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Healthcare Stocks to Watch in 2027
Which are the best healthcare stocks to watch in 2027?
Ans. Dr Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostic Centre are three of the strongest healthcare stocks to watch in 2027 based on reported numbers. Metropolis combines the fastest recent profit growth with the lowest valuation, while Dr Lal PathLabs earns the highest return on equity. The strongest figures in the group are 42.7% quarterly profit growth, a 21.32% return on equity and a PE of 51.93. Each company covers a different part of the healthcare space, so the best choice depends on whether an investor prefers growth, value or capital efficiency. Investors should match the pick to their own risk profile and holding period.
Which healthcare stock has grown profit the fastest?
Ans. Metropolis Healthcare has grown profit the fastest among these three, with September 2026 quarter net profit up 42.7% year on year to Rs 75.48 crore. Vijaya Diagnostic follows with 37.4% growth. Metropolis's latest annual net profit stood at Rs 191.18 crore for FY26. Quarterly growth can swing with seasonality and one-time items, so investors should compare several quarters before drawing conclusions. Margins and demand trends over the next two quarters will show whether this pace can continue into 2027.
Which of these healthcare stocks is the most attractively valued?
Ans. Metropolis Healthcare is the most attractively valued of the three, with a PE of 51.93 against an industry PE of 63.96. Dr Lal PathLabs trades at 56.08 and Vijaya Diagnostic at 77.66. A lower PE can signal value, but it can also reflect slower growth or higher risk, so it should be read with profit growth and return on equity. Investors should also check where each stock trades within its 52-week range before deciding on an entry point.
Why do diagnostic stocks trade at high PE ratios?
Ans. Diagnostic stocks trade at high PE ratios because they combine steady growth, high returns on equity and very little debt. Dr Lal PathLabs earns a 21.32% ROE with a debt-to-equity ratio of 0.09, and Vijaya Diagnostic earns 19.26%. These businesses also generate cash upfront, since patients pay at the time of the test. Even so, PE ratios of 56.08 to 77.66 mean investors are paying in advance for growth, so they should track quarterly test volumes and margins closely.
What are the key risks for healthcare stocks in 2027?
Ans. The main risks for healthcare stocks in 2027 are price competition, regional concentration and valuation. Online diagnostic platforms and hospital labs offer discounts that can pressure pricing. Valuation is another risk, since Vijaya Diagnostic trades above the industry PE. Each chain earns a large share of revenue from one region, so local competition matters. Investors should review quarterly results, avoid putting too much money into a single stock, and size positions according to their risk tolerance.
Should I invest in healthcare stocks for the long term?
Ans. Healthcare stocks can suit long-term investors who understand the sector's cycles and are comfortable with price swings. Dr Lal PathLabs, Metropolis and Vijaya Diagnostic have shown profit growth and healthy returns on equity, which are good signs for long-term holders. Dr Lal PathLabs earns a 21.32% return on equity, which shows how efficiently it uses shareholder money. Building positions gradually, for example through staggered purchases, usually works better than buying a full position at once. Before investing, check your asset allocation and consider speaking with a SEBI-registered investment adviser.
Recent Articles

Ahlada Engineers Analyst Review 2027: Revenue Jumps 87% but Profit Stays Near Zero
19 November 2026

Agro Phos Analyst Review 2027: Sales and Profit Slip in Q2 as Stock Nears Yearly Low
19 November 2026

Agri-Tech India Analyst Review 2027: Tiny Revenue and Steady Losses, but Stock at Half of Book
19 November 2026

Agarwal Industrial Analyst Review 2027: Q2 Profit Up 30% but Stock Sits 51% Below Its High
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Ahlada Engineers Analyst Review 2027: Revenue Jumps 87% but Profit Stays Near Zero
Agro Phos Analyst Review 2027: Sales and Profit Slip in Q2 as Stock Nears Yearly Low
Agri-Tech India Analyst Review 2027: Tiny Revenue and Steady Losses, but Stock at Half of Book
Agarwal Industrial Analyst Review 2027: Q2 Profit Up 30% but Stock Sits 51% Below Its High
Akme Fintrade Analyst Review 2027: AUM Crosses ₹1,000 Crore as Profit Rises 19%
Popular this week
Affordable Robotic Analyst Review 2027: Q2 Rebound to ₹6.47 Crore Profit on ₹149 Crore Order Book

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





